Quick Answer
DEXCOM INC reported Stockholders Equity of $2.75 billion for the year ending 2025.
- DEXCOM INC showed an increase of +30.6% in Stockholders Equity from 2024 to 2025.
- This data is from DEXCOM INC's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $1.64 billion | Q2 2021: $1.75 billion | Q3 2021: $1.91 billion | Q1 2022: $2.19 billion | Q2 2022: $2.26 billion | Q3 2022: $1.82 billion | Q1 2023: $2.23 billion | Q2 2023: $2.10 billion | Q3 2023: $2.27 billion | Q1 2024: $2.25 billion | Q2 2024: $2.43 billion | Q3 2024: $1.98 billion | Q1 2025: $2.27 billion | Q2 2025: $2.57 billion | Q3 2025: $2.73 billion.
- Over the full 8 years of available data (2018 to 2025), DEXCOM INC's Stockholders Equity has grown by 314.0%.
- Historical annual values: Fiscal year 2025: $2.75 billion | Fiscal year 2024: $2.10 billion | Fiscal year 2023: $2.07 billion | Fiscal year 2022: $2.13 billion | Fiscal year 2021: $2.04 billion | Fiscal year 2020: $1.55 billion | Fiscal year 2019: $882.60 million | Fiscal year 2018: $663.30 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: